A histopathological study on combined hepatocellular and cholangiocarcinoma: Cholangiocarcinoma component is originated from hepatocellular carcinoma

被引:1
|
作者
Wakasa, Tomoko
Wakasa, Kenichi
Shutou, Taichi
Hai, Seikan
Kubo, Shoji
Hirohashi, Kazuhiro
Umeshita, Koji
Monden, Morito
机构
[1] Osaka City Univ, Grad Sch Med, Dept Diagnost Pathol, Abeno Ku, Osaka, Osaka 5458586, Japan
[2] Osaka City Univ, Grad Sch Med, Dept Hepatobiliary & Pancreat Surg, Osaka, Osaka 5458586, Japan
[3] Osaka Univ, Grad Sch Med, Dept Surg & Clin Oncol, Suita, Osaka, Japan
关键词
combined hepatocellular and cholangiocarcinoma; hepatic neoplasm; Ki-67 labeling index; metaplasia;
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: Combined hepatocellular and cholangiocarcinoma of the liver is relatively infrequent, and its pathogenesis remains obscure. The aim of this study is to investigate its clinical and pathological features and proliferative activity. Methodology: In this study, we investigated the histopathological features, Ki-67 labeling index, and p53 immunohistochemistry of 18 surgically resected cases of combined hepatocellular and cholangiocarcinoma among 1102 consecutive cases of surgically resected primary liver cancers. All tumors were compatible with the WHO definition of this tumor. Microscopically, we classified the cases into the following three categories according to the arrangement of the hepatocellular carcinoma and cholangiocarcinoma components; 1) Type I in which hepatocellular carcinoma and cholangiocarcinoma formed nodules that could easily be distinguished from each other, 2) Type II in which the both components were finely mixed, so that the two components were almost indistinguishable, and 3) Type III in which the tumors had lobular structures with hepatocellular carcinomas existing centrally and cholangiocarcinomas existing peripherally. Results: Microscopically, the tumors were classified into type 17 tumors, type 115 tumors, and type 1116 tumors. In one case of type I, well differentiated hepatocellular carcinoma demonstrated cholangiocarcinoma in "nodules-in-nodules" fashion. The average of Ki-67 labeling index of hepatocellular carcinoma component of combined hepatocellular and cholangiocarcinoma was 4.4 +/- 3.4% and the index of cholangiocarcinoma component was 11.0 +/- 8.5%, which is significantly higher than that of the hepatocellular carcinoma component. On p53 immunohistochemistry, 5 of 18 cases (29.4%) were positive. In one case, the cholangiocarcinoma, component was positive for p53, but the hepatocellular carcinoma component was negative. In the other 4 cases, both the hepatocellular carcinoma and cholangiocarcinoma components were positive. Conclusions: Microscopically, type III seems to be a feature of metaplasia or proliferation of bipotential progenitor cells. Metaplasia of hepatocellular carcinoma to intrahepatic cholangiocarcinoma is assumed to be one of the pathogenic pathways of combined hepatocellular and cholangiocarcinoma.
引用
收藏
页码:508 / 513
页数:6
相关论文
共 50 条
  • [41] Combined hepatocellular-cholangiocarcinoma: A clinicopathological study
    Ng, IOL
    Shek, TWH
    Nicholls, J
    Ma, LT
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1998, 13 (01) : 34 - 40
  • [42] Cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in cirrhotic patients
    Salinas, Marcelo
    Simian, Daniela
    Carreno, Laura
    Cattaneo, Maximo
    Urzua, Alvaro
    Saure, Alex
    Lembach, Hanns
    Castillo, Jaime
    Diaz, Juan C.
    Poniachik, Jaime
    REVISTA MEDICA DE CHILE, 2022, 150 (11) : 1431 - 1437
  • [43] Comparison of Imaging and Clinically Relevant Features of Combined Hepatocellular Carcinoma and Cholangiocarcinoma with Hepatocellular Carcinoma
    Huang, Xialing
    Li, Yajuan
    Long, Liling
    MEDICAL SCIENCE MONITOR, 2019, 25 : 8595 - 8601
  • [44] Mixed Hepatocellular Cholangiocarcinoma and Intrahepatic Cholangiocarcinoma in Patients Undergoing Transplantation for Hepatocellular Carcinoma
    Sapisochin, Gonzalo
    Fidelman, Nicholas
    Roberts, John P.
    Yao, Francis Y.
    LIVER TRANSPLANTATION, 2011, 17 (08) : 934 - 942
  • [45] Hepatocellular carcinoma and cholangiocarcinoma: an update
    Yazici, Cemal
    Niemeyer, David J.
    Iannitti, David A.
    Russo, Mark W.
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2014, 8 (01) : 63 - 82
  • [46] Is it necessary to distinguish between combined hepatocellular carcinoma-cholangiocarcinoma with less than 10% of cholangiocarcinoma components versus hepatocellular carcinoma?
    Zhou, Changwu
    Yang, Chun
    Zeng, Mengsu
    HEPATOLOGY INTERNATIONAL, 2024,
  • [47] Transplantation for Hepatocellular Carcinoma and Cholangiocarcinoma
    Campos, B. Daniel
    Botha, Jean F.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2009, 7 (04): : 409 - 416
  • [48] Pharmacogenetics of hepatocellular carcinoma and cholangiocarcinoma
    Alonso-Pena, Marta
    Sanchez-Martin, Anabel
    Sanchon-Sanchez, Paula
    Soto-Muniz, Meraris
    Espinosa-Escudero, Ricardo
    Marin, Jose J. G.
    CANCER DRUG RESISTANCE, 2019, 2 (03) : 680 - 709
  • [49] Quantitative Assessment of Hypovascular Component in Arterial Phase to Help the Discrimination of Combined Hepatocellular-Cholangiocarcinoma and Hepatocellular Carcinoma
    Yang, Xue
    Chang, Jing
    Li, Ruili
    Qi, Yu
    Zeng, Xufen
    Wang, Wei
    Li, Hongjun
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2023, 10 : 113 - 122
  • [50] Mucin in primary liver carcinomas: Combined hepatocellular cholangiocarcinoma or variant hepatocellular carcinoma
    Hirota, S
    Nomoto, M
    Hosobe, S
    Aoyagi, Y
    Asakura, H
    CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1996, 10 (01): : 12 - 16